Biomarker testing in advanced NSCLC has increased in recent years, but turnaround time has remained roughly the same, data suggest.

Genetic testing helps determine whether any specific gene mutations are driving your lung cancer. Once a mutation is identified, a doctor may modify your cancer treatment to target it. A genetic ...

Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor (“EGFRi”) to ...

Panelists discuss the presentation and management of a case involving HER2-mutated metastatic non–-small cell lung cancer ...

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and ...

This test can help your team determine if and how ... This helps to determine a person’s treatment plan and prognosis. The ...

The KRAS and epidermal growth factor receptor (EGFR) mutations are among the most common gene mutations doctors test for in NSCLC. A doctor or pathologist can use various techniques to test for ...

The test is also approved to identify adult patients with locally advanced or metastatic rearranged during transfection (RET) fusion-positive non-small-cell lung cancer (NSCLC) that may benefit from ...

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...